Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5948Pancreatic Neoplasms 3563Carcinoma, Hepatocellular 3273Stomach Neoplasms 3057Colonic Neoplasms 2328Rectal Neoplasms 2192Esophageal Neoplasms 1801Liver Neoplasms 1247Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 871Carcinoma, Non-Small-Cell Lung 794Lung Neoplasms 745Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 585Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 304Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

gossypol acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Esophageal or GE Junction Cancer × Gastrointestinal × Clear all
NCT00561197 2013-01-04

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Ascenta Therapeutics

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Locally Advanced Esophageal or GE Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡